Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Systemic Lupus Erythematosus

Insight into Endothelial Dysfunction in Early SLE Patients without Cardiovascular Disease

Arthritis Care & Research  |  August 30, 2018

The early identification of endothelial dysfunction may be useful in clinical practice to prevent SLE patients from developing atherosclerosis and cardiovascular disease. New research evaluated the use of peripheral arterial tonometry in assessing endothelial dysfunction in patients with early SLE and no cardiovascular risk factors or disease. The results: These patients showed a high rate of endothelial dysfunction and vascular stiffness…

Critieria, Pathogenesis Highlight New Lupus Efforts

Natasha Yetman  |  August 22, 2018

Clinicians and researcher are gaining tools and insights into SLE, with newly proposed classification criteria and new findings on SLE pathogenesis presented at the 2018 EULAR: Annual European Congress of Rheumatology…

The ACR Helps Diversify Lupus Research

Susan Bernstein  |  August 17, 2018

While African Americans and Hispanics—especially women in these ethnic groups—are disproportionately affected by lupus, they are under-represented in clinical trials in lupus and other chronic diseases.1,2 With the help of a new federal grant, the ACR took the first step to address this lack of diversity in lupus trials this year. The ACR’s Collaboration Initiatives…

Atacicept Shows Promise in Lupus Treatment Trials

Mary Beth Nierengarten  |  August 17, 2018

A new biologic agent for treatment of systemic lupus erythematosus (SLE) being tested in clinical trials is showing promise as a safe and effective new treatment, particularly in patients with more severe disease or serologically active disease. Recently published results of a study that examined the safety and efficacy of atacicept for SLE showed the…

Studies Find More Evidence the Microbiome Affects Autoimmune Disease

Kurt Ullman  |  August 17, 2018

Evidence is accumulating that the microbiome may be an important part of the pathogenesis of many autoimmune diseases. Two recently published articles report on how translocation of the gut bacterium Enterococcus gallinarum drives autoimmunity in mice and humans, and on the role of other commensal bacteria in triggering immune responses—specifically to the autoantigen Ro60, which…

New Study Works Toward Better Lupus Classification Criteria

Kelly Tyrrell  |  August 16, 2018

In 1982, the ACR developed classification criteria for the identification of systemic lupus erythematosus (SLE) for use in research. The ACR updated these criteria in 1997, and in 2012, the Systemic Lupus International Collaborating Clinics (SLICC) group developed an additional set of classification criteria. In 2014, in an attempt to establish and refine even more…

SLE Is a Leading Cause of Death Among Women

Arthritis & Rheumatology  |  July 31, 2018

Systemic lupus erythematous (SLE) is a chronic inflammatory disease that predominantly affects women and can involve virtually any organ. The authors of this study analyzed secular trends and population characteristics associated with SLE mortality. Objective: Mortality statistics from the Centers for Disease Control and Prevention (CDC) are used for planning healthcare policy and allocating resources….

COIN Launches Playbook to Reach Young Adult Audiences

From the College  |  July 19, 2018

The ACR’s Collaborative Initiatives (COIN) department develops and tests innovative solutions for complex rheumatology care problems. “All of the work COIN does—programs toward health equity, creating models to increase rheumatology-related capacity in places of need, building bridges with local and national patient organizations—is done on [behalf of its members],” says Dr. David Daikh. Each month…

Phase 3 Trial Results: Blisibimod for Lupus Shows Possible Efficacy

Renée Bacher  |  July 19, 2018

A phase 3 clinical trial in which researchers treated lupus patients with blisibimod, a biologic treatment that inhibits B cell activating factor (BAFF), did not meet its primary endpoint, but did demonstrate evidence of possible efficacy. Researcher Joan T. Merrill, MD, a member of the Oklahoma Medical Research Foundation (OMRF) and OMRF professor of medicine…

Epratuzumab May Work for SLE Subgroups

Larry Beresford  |  July 19, 2018

A recent analysis of the monoclonal antibody epratuzumab finds new evidence for its effectiveness in a subset of systemic lupus erythematosus (SLE) patients who have a concurrent diagnosis of Sjögren’s syndrome, a progressive autoimmune disease that affects exocrine glands and is characterized by dry eyes and mouth.1 Sjögren’s can be primary, meaning independent of other…

  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 45
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences